Gilead Buys Oral IL-23R Inhibitor for $1.275B

Gilead Sciences is significantly expanding its immunology arsenal by acquiring an investigational oral IL-23 receptor inhibitor program, headlined by the asset HCXT-2001, from privately held PepStar Therapeutics. This strategic move, valued at an upfront payment of $1.275 billion, aims to fortify Gilead's presence in the inflammatory disease arena, particularly for conditions like Inflammatory Bowel Disease (IBD).

The newly acquired compound, HCXT-2001, represents a macrocyclic peptide designed to inhibit the IL-23 receptor pathway. Its oral administration and extended half-life position it as a potentially differentiated therapeutic option within a market increasingly seeking convenient and effective treatments for chronic inflammatory conditions. The IL-23 pathway is a well-established target, showing promise not only in IBD but also in other immune-mediated disorders such as psoriasis, a sector that has seen substantial investment and innovation.

This acquisition underscores Gilead's commitment to building a robust and diversified inflammation portfolio. The company is actively pursuing multiple therapeutic mechanisms and modalities to address complex immune-mediated diseases. By integrating HCXT-2001, Gilead gains a promising candidate that could potentially be used as a monotherapy or in combination with its existing pipeline assets, including emvistegrast, offering a daily oral treatment regimen for patients grappling with IBD.

Dr. Dietmar Berger, Chief Medical Officer at Gilead, highlighted the strategic importance of this deal, stating, “HCXT-2001 adds a potentially differentiated oral approach to our growing inflammation pipeline, reflecting our commitment to addressing significant unmet patient needs.” The company anticipates that the transaction will close by the fourth quarter of 2026, subject to standard closing conditions. This move aligns with broader industry trends where pharmaceutical giants are actively seeking to acquire innovative early- and mid-stage assets to fill their development pipelines and maintain a competitive edge.

The deal represents a significant milestone for PepStar Therapeutics, validating its proprietary oral peptide platform. Haibing Guo, Founder and CEO of PepStar, expressed enthusiasm for Gilead's capabilities in advancing HCXT-2001. “We are excited for Gilead to take HCXT-2001 forward and believe their scientific expertise and global development capabilities can help realize the full potential of this novel oral IL-23R inhibitor,” Guo remarked. This transaction highlights the value creation potential within the biotechnology sector for companies developing novel drug candidates targeting validated biological pathways.

The acquisition of HCXT-2001 by Gilead is a strategic play in the competitive immunology market, which is projected for continued growth driven by increasing disease prevalence and advancements in therapeutic understanding. The global IBD market alone is substantial and continues to expand, creating a strong demand for novel treatment options. By securing this oral IL-23R inhibitor, Gilead positions itself to capture a significant share of this evolving market, enhancing its therapeutic offerings and reinforcing its leadership in the immunology space.